Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Hertz

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncologyDaniel L Hertz, Howard L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2016
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of UtilityDaniel L Hertz, James M Rae
Advances in Experimental Medicine and Biology|March 19, 2016
Pharmacogenetic Predictors of ResponseDaniel L Hertz, James M Rae
Pharmacogenomics|June 2, 2016
One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validityDaniel L Hertz, James M Rae
Journal of Human Genetics|May 17, 2013
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicityDaniel L Hertz, Howard L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Tamoxifen Dose Escalation-ResponseDaniel L Hertz, James M Rae
JCO Precision Oncology|July 10, 2025
Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision DosingDaniel L Hertz, Alan P Venook
Cancer Chemotherapy and Pharmacology|May 11, 2024
Using maximum plasma concentration (C<sub>max</sub>) to personalize taxane treatment and reduce toxicityYuchen Sun, Yue Cheng, Daniel L Hertz
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 29, 2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicityDaniel L Hertz, Maryam B Lustberg, Stephen Sonis
Pharmacogenomics|April 10, 2018
CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administrationAmy L Pasternak, Lu Zhang, Daniel L Hertz
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncologyDaniel L Hertz, Howard L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2016
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of UtilityDaniel L Hertz, James M Rae
Advances in Experimental Medicine and Biology|March 19, 2016
Pharmacogenetic Predictors of ResponseDaniel L Hertz, James M Rae
Pharmacogenomics|June 2, 2016
One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validityDaniel L Hertz, James M Rae
Journal of Human Genetics|May 17, 2013
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicityDaniel L Hertz, Howard L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Tamoxifen Dose Escalation-ResponseDaniel L Hertz, James M Rae
JCO Precision Oncology|July 10, 2025
Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision DosingDaniel L Hertz, Alan P Venook
Cancer Chemotherapy and Pharmacology|May 11, 2024
Using maximum plasma concentration (C<sub>max</sub>) to personalize taxane treatment and reduce toxicityYuchen Sun, Yue Cheng, Daniel L Hertz
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 29, 2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicityDaniel L Hertz, Maryam B Lustberg, Stephen Sonis
Pharmacogenomics|April 10, 2018
CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administrationAmy L Pasternak, Lu Zhang, Daniel L Hertz
Pageof 14